Background/Aims: Conventional time domain optical coherence tomography (OCT) has become an important diagnostic tool to measure retinal thickness in clinical routine. Recently, different models of high-speed, high-resolution frequency domain OCTs have been introduced by various manufacturers. The purpose of this study was to compare 3 commercially available OCT models for retinal thickness measurements in healthy controls. Methods: OCT scans were performed on 28 healthy eyes with the RTVue-100 FD-OCT (Optovue Inc., USA), the Cirrus™ HD-OCT (Carl Zeiss Meditec Inc., USA) and the Stratus OCT 3000 (Carl Zeiss Meditec Inc.). Retinal thickness values were calculated and compared between OCT models. Results: Differences in mean retinal thickness measurements between OCT models were statistically significant. Mean retinal thickness measurement with Cirrus OCT, RTVue OCT and with Stratus OCT was 300, 265 and 257 μm, respectively. Conclusion: Measurements with different OCT models lead to significantly different retinal thickness values.

1.
Jean B, Frohn A, Thiel JH: Laser scanning in ophthalmology. Fortschr Ophthalmol 1990;87:158–167.
2.
Huang D, Swanson EA, Lin CP, et al: Optical coherence tomography. Science 1991;254:1178–1181.
3.
Hee MR, Izatt JA, Swanson EA, et al: Optical coherence tomography of the human retina. Arch Ophthalmol 1995;113:325–332.
4.
Puliafito CA, Hee MR, Lin CP, et al: Imaging of macular diseases with optical coherence tomography. Ophthalmology 1995;102:217–229.
5.
Choma MA, Sarunic MV, Yang C, Izatt JA: Sensitivity advantage of swept source and Fourier domain optical coherence tomography. Opt Express 2003;11:2183–2189.
6.
Wojtkowski M, Srinivasan V, Fujimoto JG, et al: Three-dimensional retinal imaging with high-speed ultrahigh-resolution optical coherence tomography. Ophthalmology 2005;112:1734–1746.
7.
Wojtkowski M, Srinivasan V, Ko T, Fujimoto JG, Kowalczyk A, Duker JS: Ultrahigh-resolution, high-speed, Fourier domain optical coherence tomography and methods for dispersion compensation. Opt Express 2004;12:2404–2422.
8.
Wojtkowski M, Srinivasan V, Ko T, et al: High speed, ultrahigh resolution retinal imaging using spectral/Fourier domain OCT. Conf Lasers Electrooptics 2005;3:2058–2060.
9.
Srinivasan VJ, Wojtkowski M, Witkin AJ, et al: High-definition and 3-dimensional imaging of macular pathologies with high-speed ultrahigh-resolution optical coherence tomography. Ophthalmology 2006;113:2054–2065.
10.
Alam S, Zawadzki RJ, Choi S, et al: Clinical application of rapid serial Fourier-domain optical coherence tomography for macular imaging. Ophthalmology 2006;113:1425–1431.
11.
Schmid-Erfurth U, Leitgeb RA, Michels S, et al: Three-dimensional ultrahigh-resolution optical coherence tomography of macular diseases. Invest Ophthalmol Vis Sci 2005;46:3393–3402.
12.
Ahlers C, Geitzenauer W, Simader C, et al: New perspectives in diagnostics: high-resolution optical coherence tomography of age-related macular degeneration. Ophthalmologe 2008;105;248–254.
13.
Menke MN, Dabov S, Sturm V: Features of age-related macular degeneration assessed with 3-dimensional Fourier-domain optical coherence tomography. Br J Ophthalmol 2008;92:1492–1497.
14.
Menke MN, Knecht P, Sturm V, Dabov S, Funk J: Reproducibility of Nerve Fiber Layer Thickness Measurements using 3D Fourier-Domain OCT (Topcon 3d-OCT1000). Invest Ophthalmol Vis Sci 2008;49:5386–5391.
15.
Photocoagulation for diabetic macular edema: Early treatment diabetic retinopathy study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985;103:1796–1806.
16.
Fung AE, Lalwani GA, Rosenfeld PJ, et al: An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566–583.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.